Feb 2, 2023 4:01 pm EST Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock and Warrants
Jan 17, 2023 7:00 am EST Avalo Announces it Has Completed Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic Asthma
Nov 7, 2022 7:30 am EST Avalo Reports Third Quarter 2022 Financial Results and Provides Business Updates
Aug 4, 2022 7:30 am EDT Avalo Reports Second Quarter 2022 Financial Results and Provides Business Updates
Aug 2, 2022 7:30 am EDT Avalo Therapeutics Announces First Patient Dosed in the AVTX-803 Pivotal Trial (LADDER) for the Treatment of Leukocyte Adhesion Deficiency Type II (LAD II)
Aug 1, 2022 7:00 am EDT Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics
